Buy
Sell
Share Name Share Symbol Market Type Share ISIN Share Description
Motif Bio Plc LSE:MTFB London Ordinary Share GB00BVVT4H71 ORD 0.01P
  Price Change % Change Share Price Shares Traded Last Trade
  0.00 0.0% 0.50 0.00 01:00:00
Bid Price Offer Price High Price Low Price Open Price
0.40 0.55
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceuticals & Biotechnology -0.54 3
Last Trade Time Trade Type Trade Size Trade Price Currency
- O 0 0.50 GBX

Motif Bio (MTFB) Latest News

More Motif Bio News
Motif Bio Investors    Motif Bio Takeover Rumours

Motif Bio (MTFB) Discussions and Chat

Motif Bio (MTFB) Most Recent Trades

No Trades
Trade Time Trade Price Trade Size Trade Value Trade Type
View all Motif Bio trades in real-time

Motif Bio (MTFB) Top Chat Posts

DateSubject
19/6/2021
09:20
Motif Bio Daily Update: Motif Bio Plc is listed in the Pharmaceuticals & Biotechnology sector of the London Stock Exchange with ticker MTFB. The last closing price for Motif Bio was 0.50p.
Motif Bio Plc has a 4 week average price of 0p and a 12 week average price of 0p.
The 1 year high share price is 0.78p while the 1 year low share price is currently 0.32p.
There are currently 654,991,023 shares in issue and the average daily traded volume is 0 shares. The market capitalisation of Motif Bio Plc is £3,274,955.12.
16/6/2021
21:21
hedgehog 100: Tnt99, No listing means that there is little or no attraction for a RTO candidate, and in any case a RTO requires a lot of time and money to arrange. MTFB's main value was its listing which has now been lost. In contrast MTFB's liabilities will have mounted up considerably. Accrued deferred payments to directors, and aborted RTO costs, with no money now coming in from the RTO placing. In summary, administration looks like the overwhelmingly likely outcome here, and always did if the RTO was voted down. There was never any chance of an alternative deal, not least because AIM time limits required an immediate delisting after the RTO was aborted. Under AIM rules, there are relatively short time limits to arrange a RTO. MTFB had already been granted a four and a half month extension, probably because of COVID-19.
15/6/2021
08:36
onei: Watching this with interest and some disappointment. I don't know any of the Board of Directors or posters on here but seems to me that a breakdown in trust between the two has led to an end result of "Cutting nose to spite face" Correct me if I am wrong but: Company ran out of cash and only options left were to sell, merge or be taken over as a shell. ie existing shareholders not prepared to put up enough money to continue in business. Proposed reverse takeover gives shareholders a value of less than 0.1p for each existing share (ie before any consolidation) but without a transaction they most likely will get no value. A significant minority of shareholders (more than 25% but less than 50%) have effectively voted to receive no value. The reason being a desire to deprive the Board of Directors of a benefit ( and no, I don't know what this benefit might be.) Now I can see that it is galling for Mr Gold to carry on as a Director after being part of such value destruction, and I have no idea how responsible he is. But wouldn't it have been better just to vote against him at the next AGM? Or maybe tell the NOMAD that you are going to vote down the whole proposal unless he goes? What particularly puzzled me was that the dissenters voted down the resolution to consolidate the shares. This is a resolution that does nothing to alter the value of anybody's shareholding. (You get 1 share for every 220 but they are worth 220 times as much.) The end result is that the substantial minority has actually deprived the majority from receiving any value. Is that morally right?
11/6/2021
01:01
w t tutte: SD70, Unfortunately I am not sure at this end of town stronger CG guidelines will help a great deal. I think the only thing that really helps at is skin in the game from the management and board or a well respected (active) substantial shareholder. I also see an inverse correlation between a very active LSE chat board or the number of chuffer types that you get who are so absolutist in their views and the quality of the company. But there in lies the attraction of AIM. It is like a used car lot, 90% of the cars on the lot are lemons, 10% are not, but all the cars on the lot are priced like lemons. If you can find that 10% you will be golden. I think Ms Thorn is going to a huge improvement on this shower, ultimately the science has to be proven, but I think the prospects of getting it to a point where it will be taken in to the clinic by big pharma are decently high. They are more than fully funded to get to that point. If they are successful at that point the share price will be multiples higher, it could easily be between GBP2 and GBP5. I am hopeful next week they will do a lot of introductory publicity as the approach she is taking is so elegantly simple you wonder why it has not been done before. The answer to that is that the manufacturing of the linker binding arms is hugely specialised and complex, however she had been working at ADCBio who specialise in this area and are world renowned and will be using some of their capabilities and licensed technology.
08/6/2021
08:42
w t tutte: Yes, its awful and it should not change how you feel, but MTFB was always at the spivy end of what is a spivy market. I am not trying to invalidate what you are saying or feeling but to my view you are mixing up the history of how we go here with what is the best shareholders today. We are where we are, however we got here. What is best for shareholders given this is where we are, is for the RTO to proceed. As you will see next week most shareholders will not be principled like you, they will salvage a little something and move on.
08/6/2021
08:34
scottdavid70: Yes the price is high but I have voted No and I will tell you why and it’s really simple Had the Board had the decency and courage to reply to shareholders questions these past 2 years - take less money in salaries to minimise dilution I would have felt differently too but the real kicker here was - The warrant price - after all that has gone on they still feel they deserve free shares and at a better price than the shareholders who bought shares off the back of the directions they gave. The Directors didn’t buy shares yet deem it right to have more warrants at a better price for ONE Director than the ENTIRE REST of the shareholders. No one can argue that is in the BEST INTERESTS OF SHAREHOLDERS not even OJ Simpsons lawyer
08/6/2021
08:14
w t tutte: SD70, I am not defending the board, look back, I have said the only way to hurt them is to sue them for negligence, it is the only way. In every other scenario they win. In my view MTFB management and board have been a complete shower at every turn and if they have been negligent or even fraudulent they should be held accountable. But the stark truth is we are where we are, there is no value left in MTFB and there is no time to find alternatives before the liquidators are called in. You say you have 11.5 million shares ? At the RTO price that is worth GBP 10,555, there is clearly upside to that price and with the warrants it is not inconceivable within 18 months you could have many multiples of that amount. The amount you are prepared to sacrifice to make a point seems high. If the RTO were to be voted down they win and you get nothing, the RTO goes through they win and you get something. I prefer the later myself, anyway it is all semantic as it will go through of that I am certain. On a slightly different note, if you read the proxy form it says they will broadcast the GM and that they will take questions but that these must be submitted by email no later than tomorrow. That might be route for you to get some of the answers you are looking for.
08/6/2021
07:17
w t tutte: I also find it a bit laughable that some people seem to be against the share consolidation, when it is the merger ratio that cause the dilution. If I have 220 shares at 1p or 1 share at 220p as long as this is applied to all shareholders my percentage ownership of the company does not change. It is only when the comparative value of MTFB and BiVictrix are put together that the dilution occurs.
27/5/2021
07:30
dafad: RNS Number : 9555Z Adams PLC 27 May 2021 Adams plc ("Adams" or the "Company") Investment in Motif Bio Plc ("Motif Bio") to be renamed BiVictriX Therapeutics Plc upon readmission to AIM The Directors announce that, further to the announcement made on 26 May 2021 by Motif Bio referred to below, Adams has committed to subscribe for 2,500,000 new ordinary shares of 2.2p each in Motif Bio ("New Ordinary Shares") at a price of 20 pence per share for a total cash consideration of £500,000 under a conditional placing agreement. The announcement released by Motif Bio on 26 May 2021 discloses that it has entered into a conditional contract for the acquisition of the entire issued share capital of BiVictriX Therapeutics Limited ("BiVictriX") for an aggregate consideration of £5,500,608 to be satisfied by the issue of New Ordinary Shares in Motif Bio and cash, and that it has also conditionally raised gross proceeds of £10.1 million by way of a placing and subscription issue of 50,500,000 New Ordinary Shares to new and existing shareholders. The acquisition of BiVictriX constitutes a "reverse takeover" under Rule 14 of the AIM Rules for Companies, and accordingly is subject to the approval of Motif Bio shareholders, which is being sought at a General Meeting convened for 14 June 2021. As part of the above acquisition and fundraising proposals, the Motif Bio directors believe that it is in the best interests of the company for there to be a share consolidation (the "Share Consolidation") of 1 New Ordinary Share for every 220 existing ordinary share of 0.01p in Motif Bio ("Existing Ordinary Shares") to reduce the number of ordinary shares in issue, which will then comprise the New Ordinary Shares of 2.2p each, and thereby increase the share price with a view to decreasing the spread between the bid and offer prices. The placing is conditional, amongst other things, upon the proposed reverse acquisition by Motif Bio of BiVictriX and its readmission to trading on AIM under the new name BiVictriX Therapeutics Plc having become effective at or around 8.00 a.m. on 15 June 2021 or such later time and date as Motif Bio and its broker agent, share price Angel, may agree (being not later than 8.00 a.m. on 2 July 2021). Following the Share Consolidation and assuming the maximum number of New Ordinary Shares are issued pursuant to the above BiVictriX acquisition and fund raise proposals, the issued ordinary share capital of Motif Bio will comprise 80,979,876 New Ordinary Shares upon readmission to trading on AIM. Adams's holding of 2,500,000 New Ordinary Shares in Motif Bio will represent 3.09% of the company's maximum number of 80,979,876 New Ordinary Shares in issue upon readmission to trading on AIM as BiVictriX Therapeutics Plc, which is currently expected to take place on or around 15 June 2021. Adams is expected to have remaining cash balances of approximately £2.69 million following this investment. Richard Griffiths, who has an interest in 80.3% of Adams' issued share capital, has no current interest in Motif Bio shares but is also subscribing in his personal capacity for 2,500,000 New Ordinary Shares in Motif Bio under the Placing at a price of 20 pence per share for a consideration of £500,000. Following completion of the Placing, Mr Griffiths will have a total interest in 5,000,000 New Ordinary Shares, including those shares held by Adams, representing 6.17% of the enlarged share capital of Motif Bio as renamed BiVictriX Therapeutics Plc. About Motif Bio Motif Bio was incorporated in England on 20 November 2014 and was admitted to trading on AIM in April 2015. Motif Bio was a drug discovery and development company with a specific focus on its antibiotic product candidate, iclaprim, a treatment for acute bacterial skin and skin structure infections. However, following regulatory drug approval setbacks in 2019 and faced with challenging capital markets for companies with antibiotic products at that time, Motif Bio executed a restructuring which involved, amongst other things, the orderly sale/wind down of Motif Bio, Inc., its wholly owned subsidiary which held all iclaprim-related assets and operations. This restructuring was approved by Motif Bio's shareholders at a General Meeting in November 2019 and resulted in Motif Bio being reclassified as an AIM Rule 15 cash shell on 28 January 2020. The company then began searching for an appropriate reverse takeover candidate to deliver value to its shareholders which has culminated in the proposed reverse acquisition of BiVictriX. The last filed accounts for Motif Bio are for the year ended 31 December 2020 and include a loss after tax of US$0.73 million, mainly reflecting general and administrative expenses, together with net assets at that year end of US$0.46 million, inclusive of cash balances US$0.46 million. About BiVictriX BiVictriX is a UK-based oncology-focused rapidly emerging biotechnology company applying a novel approach to develop safer, more effective cancer therapies. It has developed Bi-Cygni® therapeutics, which are uniquely selective for particular cancer types, to enable higher dosing and more aggressive cancer eradication without causing harmful side-effects. BiVictriX's Bi-Cygni® technology focuses on an area of unmet medical need. BiVictriX's lead development programme, BVX001, is considered to represent a first-in-class Bi-Cygni® ADC, targeting the cancer-specific co-expression pattern of CD7 and CD33, with early preclinical validation demonstrated in AML models. AML is the most common form of adult leukaemia, (representing approximately 80 per cent. of cases) and is one of the most aggressive forms of cancer, often presenting with a fulminant clinical course. With chances of long-term survival still dismally low, AML represents an urgent unmet medical need and the global ADC market represents one of the fastest growing markets in the oncology sector. The market was valued at US$1.57 billion in 2017 and is set to grow rapidly with forecasts estimating the sector will be worth US$9.93 billion by 2025. As part of the reverse acquisition and fundraise proposals, the enlarged group will receive net proceeds of approximately £9 million (after deducting expenses) which are expected to be used to accelerate the lead optimisation of BVX001 to reach key preclinical milestones on efficacy and safety, as well as to expand BiVictriX's early-stage pipeline to include two additional candidates with preclinical proof of concept. In addition, the aim is to grow BiVictriX's intellectual property portfolio to add further protection around the lead programme potential avenues for platform intellectual property generation and defensibility of BiVictriX's approach. The directors of the enlarged group believe the Bi-Cygni® approach can be applied to build a diverse pipeline of first-in-class therapeutics across the wider spectrum of immunotherapeutic platforms, addressing key unmet medical needs in the market. BiVictriX's ambition is to validate the B-Cygni® approach within a panel of difficult-to-treat cancer indications to demonstrate to the market the wide applicability of the concept, building the enlarged group into a global leader in this field. Further information regarding BiVictriX's development to date, the strategy of the enlarged group and the market for ADC's is set out in Part II of the Motif Bio notice of general meeting document dated 26 May 2021 and which can be found on the Motif Bio website www.motifbio.com. The last filed accounts for BiVictriX are for the year ended 31 December 2020 and include a loss after tax of approximately £0.43 million, reflecting the continued investment in development in that year, together with net assets at that year end of £0.07 million, inclusive of cash balances of £0.86 million.
26/5/2021
23:16
tnt99: So if the share price of the new company say rises to 60p I could buy 5000 warrants for 30p and sell them for 60p just to clarify
26/5/2021
22:30
tnt99: Thanks chuffer so you can buy a warrant at 30p for every 2 shares you own is that correct as this has never happened to me before sorry for the ignorance are they valued the same as the share price?
Motif Bio share price data is direct from the London Stock Exchange
ADVFN Advertorial
Your Recent History
LSE
MTFB
Motif Bio
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20210619 15:23:21